Shionogi launches severe thrombocytopenia treatment drug Mulpleo®
Category: #health  By Pankaj Singh  Date: 2020-03-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Shionogi launches severe thrombocytopenia treatment drug Mulpleo®

Chronic liver disease is a critical healthcare issue in the UK, with number of deaths recorded to go up by 400% since 1970. Currently, transfusion of platelets appears to be the only treatment option available to manage platelet counts, however, pharma institutes are constantly working on developing a new, viable treatment alternative.

Reportedly, Japanese pharmaceutical company, Shionogi & Co. Ltd. and its European branch, Shionogi B.V., have recently made a striding development by launching Mulpleo® (lusutrombopag), a drug formulated to treat severe thrombocytopenia in adults suffering from chronic liver disease (CLD) and undergoing invasive procedures, in the UK.

Reportedly, Mulpleo® is the first-ever licensed treatment available on the UK’s NHS to treat this disorder. It has also bagged approval for funding across various health services in Scotland, Northern Ireland, and England & Wales.

According to reliable sources, the launch and approval of Mulpleo® were based on the findings derived from L-PLUS 2 and L-PLUS 1. Both these phase III studies are randomized, multicenter, parallel-group, double-blind, placebo-controlled for 312 CLD patients with <50,000/µL platelet count severe thrombocytopenia.

Speaking on the move, Dr. Andrew Holt, Consultant Physician (Liver, GI & HPB) at University Hospitals, Birmingham, said that the launch of Mulpleo comes as a piece of great news for CLD patients, as it bags approval from both NICE and SMC. Over the years, there has been a significant rise in patients suffering from chronic liver disease and this trend is expected to continue in the future.

To this date, doctors and CLD patients did not have any specific therapies for curing thrombocytopenia, a common complication of chronic liver disease which could delay or obscure vital interventions for CLD patients. Evidently, with the introduction of Mulpleo, physicians can now harness a valuable tool for safely facilitating these interventions, added Dr. Holt.

Source Credit: https://finance.yahoo.com/news/shionogi-announces-launch-mulpleo-lusutrombopag-000100194.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Appili gets FDA approval to expand the clinical trial of favipiravir
Appili gets FDA approval to expand the clinical trial of favipiravir
By Pankaj Singh

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application ...

Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
By Pankaj Singh

The Ministry of Health, Saudi Arabia, has reportedly announced that it will begin the third phase of clinical trials for a COVID-19 vaccine, as part of its cooperation with China’s CanSino Biologics Inc. The tria...

Amazon cleared by UK regulators to buy 16% stake in Deliveroo
Amazon cleared by UK regulators to buy 16% stake in Deliveroo
By Pankaj Singh

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to ...